More Imugene Ltd news
Imugene LtdASX: IMU

Intellectual Property Strengthened Around Lead Clinical Drug

Feb 26, 2017 at 9:50 PM EST · Issued by Imugene Ltd

Filed with ASX · Feb 26, 2017 at 9:50 PM EST · 2 pages · English

On 6ix: 6ix.com/news/intellectual-property-strengthened-around-lead-clinical-drug

Imugene Ltd on 6ix

Earlier from Imugene

  • BMC Cancer journal publishes encouraging HER-Vaxx researchFeb 12, 2017
  • Imugene progresses mimotope platformDec 18, 2016
  • Response to ASX Aware QueryDec 15, 2016
  • Acquisition of immuno-oncology technologyDec 12, 2016
  • Leslie Chong Appointed Chief Executive OfficerNov 21, 2016

Later from Imugene

  • Half Year Report and AccountsFeb 28, 2017
  • $1.35 million Options UnderwrittenMar 29, 2017
  • IMU Raises $3.0m from Options PlanApr 6, 2017
  • Appendix 4C - quarterly and Commentry Q3Apr 28, 2017
  • Imugene granted Canadian patent for Her-Vaxx cancer vaccineJul 21, 2017
All Imugene news releases↗

Follow Imugene into a list and get an email when it puts out news.

Follow Imugene
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer